Available data also suggest that, in the context of concomitant antiplatelet therapy, FXI inhibitors do not substantially increase major bleeding risk when compared with standard anticoagulation, even in patients receiving dual antiplatelet therapy after acute coronary syndrome [62,70]. This evidence concerns the gene F11 and acute coronary syndrome.